Podcasts about Precision

“Colorectal cancer treatment is not just about eliminating a disease. It's about preserving life quality and empowering patients through every phase. So I think nurses are really at the forefront that we can do that in the oncology nursing space. So from early detection to survivorship, the journey is deeply personal. Precision medicine, compassionate care, and informed decision-making are reshaping outcomes. Treatment's just not about protocols. It's about people,” ONS member Kris Mathey, DNP, APRN-CNP, AOCNP®, gastrointestinal medical oncology nurse practitioner at The James Cancer Hospital of The Ohio State University Wexner Medical Center in Columbus, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about colorectal cancer treatment.  Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 1.0 contact hour of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by August 1, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learner will report an increase in knowledge related to the treatment of colorectal cancer. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 370: Colorectal Cancer Screening, Early Detection, and Disparities Episode 153: Metastatic Colorectal Cancer Has More Treatment Options Than Ever Before ONS Voice articles: Colorectal Cancer Prevention, Screening, Treatment, and Survivorship Recommendations Genetic Disorder Reference Sheet: Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) How Liquid Biopsies Are Used in Cancer Treatment Selection Oncology Drug Reference Sheet: 5-Fluorouracil Oncology Drug Reference Sheet: Oxaliplatin What Is a Liquid Biopsy? Clinical Journal of Oncology Nursing article: Colorectal Cancer in Young Adults: Considerations for Oncology Nurses Oncology Nursing Forum article: Neurotoxic Side Effects Early in the Oxaliplatin Treatment Period in Patients With Colorectal Cancer ONS Colorectal Cancer Learning Library ONS Biomarker Database (filtered by colorectal cancer) ONS Peripheral Neuropathy Symptom Interventions American Cancer Society colorectal cancer resources CancerCare Colorectal Cancer Alliance Colorectal Cancer Resource and Action Network Fight Colorectal Cancer National Comprehensive Cancer Network To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Colorectal cancer has several different types, but there is one that dominates the landscape, and that is adenocarcinoma. So I think most of us have heard that. It's fairly common, and it accounts for about 95% of all colorectal cancers. It begins in the glandular cells lining the colon or rectum and often develops from polyps, in particular adenomatous polyps.” TS 1:41 “One of the biomarkers that we'll most commonly hear about is KRAS or NRAS mutations. This indicates tumor genetics, and these mutations suggest resistance to our EGFR inhibitors such as cetuximab. BRAF mutation or V600E is a more aggressive tumor subtype, and those may respond to our BRAF targeted therapy. … And then our MSI-high or MMR-deficient—microsatellite instability or mismatch repair deficiency—that really predicts an immunotherapy response and may indicate Lynch syndrome, which is a huge genetic component that takes a whole other level of counseling and genetic testing with our patients as well.” TS 6:02 “Polypectomy or a local excision—that removes our small tumors or polyps during that colonoscopy. And that's what's used for those stage 0 or early stage I cancers. A colectomy removes part or all of the colon. This may be open or laparoscopic. It can include a hemicolectomy, a segmental resection, or a total colectomy, so where you take out the entire part of the colon. A proctectomy removes part or all of the rectum. This may include a low anterior resection, also known as an LAR … or an abdominal perineal resection, which is an APR. … Colostomy or ileostomy—that diverts the stool to an external bag via stoma. Sometimes this is temporary or permanent depending on the type of surgery.” TS 14:11 “We'll have our patients say, ‘Hey, I want immunotherapy therapy. I see commercials on it that it works so well.' We have to make sure that these patients are good candidates for it, also that we're treating them adequately. We need to make sure that they have those biomarkers, so as I mentioned, the MSI-high or MMR tumors. Our MSS-stable tumors—they may benefit from newer combinations or clinical trials. Metastatic disease—immunotherapy may be used alone or with other treatments. And then in the neoadjuvant setting, some trials are really showing promising results using immunotherapy prior to surgery.” TS 25:38 “Antibody-drug conjugates are really an exciting frontier in all cancer treatments as well as colorectal cancer treatment. This is used mainly for patients with advanced or treatment-resistant disease, and these therapies combine the targeted power of monoclonal antibodies with the cell-killing ability of potent chemotherapy agents. They're still on the horizon for the most part in colorectal cancer. However, there is only one approved antibody-drug conjugate, or ADC, at this time, and that's trastuzumab deruxtecan, or Enhertu. That's approved for any solid tumor, such as colorectal cancer with HER2 IHC 3+. So again, looking back at that pathology in those markers, making sure that you have that HER2 mutation and that IHC.” TS 35:00 “There are a few myths going around about colorectal cancer treatment that can lead to confusion or even delayed care. One myth is only older men get colorectal cancer. As you heard me talk in my previous podcast on screening, unfortunately, this isn't necessarily true. Colorectal cancer affects both men and women and our cases in the younger population are rising. So our screening guidelines have changed to age 45 because we are seeing it in the younger population.” TS 45:54

Anthony is joined by Sarah in this episode where and they talk about their recent race in Iceland. Sarah managed to get win her age group so we get all the details on her bike, gear choice, tyres, fuelling and all the other highs and lows! A must listen episode if you have any big days out planned on the bike! NOMIO is clinically proven to:Lower lactate levels, Reduce oxidative stress, Improve training adaptations And deliver a noticeable boost from the very first dose. Go to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.drinknomio.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ and check out this game changing supplement. 4iiiiReady to elevate your cycling game? Trust the 4iiii PRECISION 3+ Powermeter—precision, performance, and peace of mind, all in one.Learn more by visiting http://www.4iiii.comREAPCustom Carbon Composition Bikes made in the UK. REAP's gravel bike is set to redefine gravel riding with 50mm+ tyre clearance https://reapbikes.com/

What happens when you build the ultimate predator rifle? Seth and Preston break down every detail of Seth's custom AR-15, chambered in 22 ARC — from barrel to buttstock. Whether you're chasing coyotes, ringing steel, or looking for the perfect youth deer rifle, this episode dives deep into the why behind each component choice. Tune in for a no nonsense walkthrough of one of the most versatile AR builds in the Hornady vault.

James Craig Case: Poison, Premeditation & Prosecutorial Precision What happens when a trusted husband, a father of six, and a respected Colorado dentist is suddenly accused of killing his wife—with cyanide, eyedrops, and protein shakes? In Part 1 of this gripping two-part breakdown, defense attorney and former prosecutor Eric Faddis joins us from inside the courthouse to dissect the case the jury is still trying to wrap their heads around. The prosecution has laid out a chilling timeline: online orders for arsenic and cyanide, Google searches like “how to make murder look like a heart attack,” and hospital visits where Angela Craig mysteriously crashed—right after being alone with James. With no eyewitnesses, no surveillance video of a fatal act, and no dramatic confession, this is a case built entirely on digital footprints, emotional devastation, and one cold, calculated timeline. But is that enough? Eric Faddis walks us through the strategy unfolding in real-time—how prosecutors are methodically connecting Amazon carts, IV access ports, and digital forensics to paint a portrait of intent. He also breaks down how the defense is trying to poke holes in the chain of evidence and float the idea that Angela may have died by suicide. But with Angela's daughters testifying that their mother was optimistic and making future plans, the suicide theory may be dead on arrival. This episode sets the stage: Was this a clinical poisoning plotted by a man who wanted out of his marriage—or a tragic medical mystery that looks too neat to be true? Get the inside view from the courtroom—and decide for yourself. #JamesCraig #TrueCrimePodcast #MurderTrial #AngelaCraig #DentistMurderCase #CyanidePoisoning #CourtroomDrama #TrialAnalysis #EricFaddis #HiddenKillersPodcast Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/@hiddenkillerspod Instagram https://www.instagram.com/hiddenkillerspod/ Facebook https://www.facebook.com/hiddenkillerspod/ Tik-Tok https://www.tiktok.com/@hiddenkillerspod X Twitter https://x.com/tonybpod Listen Ad-Free On Apple Podcasts Here: https://podcasts.apple.com/us/podcast/true-crime-today-premium-plus-ad-free-advance-episode/id1705422872

James Craig Case: Poison, Premeditation & Prosecutorial Precision What happens when a trusted husband, a father of six, and a respected Colorado dentist is suddenly accused of killing his wife—with cyanide, eyedrops, and protein shakes? In Part 1 of this gripping two-part breakdown, defense attorney and former prosecutor Eric Faddis joins us from inside the courthouse to dissect the case the jury is still trying to wrap their heads around. The prosecution has laid out a chilling timeline: online orders for arsenic and cyanide, Google searches like “how to make murder look like a heart attack,” and hospital visits where Angela Craig mysteriously crashed—right after being alone with James. With no eyewitnesses, no surveillance video of a fatal act, and no dramatic confession, this is a case built entirely on digital footprints, emotional devastation, and one cold, calculated timeline. But is that enough? Eric Faddis walks us through the strategy unfolding in real-time—how prosecutors are methodically connecting Amazon carts, IV access ports, and digital forensics to paint a portrait of intent. He also breaks down how the defense is trying to poke holes in the chain of evidence and float the idea that Angela may have died by suicide. But with Angela's daughters testifying that their mother was optimistic and making future plans, the suicide theory may be dead on arrival. This episode sets the stage: Was this a clinical poisoning plotted by a man who wanted out of his marriage—or a tragic medical mystery that looks too neat to be true? Get the inside view from the courtroom—and decide for yourself. #JamesCraig #TrueCrimePodcast #MurderTrial #AngelaCraig #DentistMurderCase #CyanidePoisoning #CourtroomDrama #TrialAnalysis #EricFaddis #HiddenKillersPodcast Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/@hiddenkillerspod Instagram https://www.instagram.com/hiddenkillerspod/ Facebook https://www.facebook.com/hiddenkillerspod/ Tik-Tok https://www.tiktok.com/@hiddenkillerspod X Twitter https://x.com/tonybpod Listen Ad-Free On Apple Podcasts Here: https://podcasts.apple.com/us/podcast/true-crime-today-premium-plus-ad-free-advance-episode/id1705422872

Forget doping—pro cycling's most impactful unfair advantage is hiding in plain sight. This video exposes the truth about TV motorbikes and team cars create powerful slipstreams that change races like the Tour de France, often determining stage wins. From Tim Wellens' 2025 victory (where Quinn Simmons was very vocal) to infamous cases involving Pogačar and Roglič, we dive into the science, history, and politics of motor drafting. With insights from wind tunnel studies, rider testimonies, and expert opinions, we explore how camera bikes can tip the scales—and why the current rules are failing.NOMIO is clinically proven to:Lower lactate levels, Reduce oxidative stress, Improve training adaptations And deliver a noticeable boost from the very first dose. Go to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.drinknomio.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ and check out this game changing supplement. 4iiiiReady to elevate your cycling game? Trust the 4iiii PRECISION 3+ Powermeter—precision, performance, and peace of mind, all in one.Learn more by visiting http://www.4iiii.comREAPCustom Carbon Composition Bikes made in the UK. REAP's gravel bike is set to redefine gravel riding with 50mm+ tyre clearance https://reapbikes.com/

In this episode, Lyell K. Jones Jr, MD, FAAN, speaks with Michael S. Okun, MD, FAAN, who served as the guest editor of the August 2025 Movement Disorders issue. They provide a preview of the issue, which publishes on August 1, 2025. Dr. Jones is the editor-in-chief of Continuum: Lifelong Learning in Neurology® and is a professor of neurology at Mayo Clinic in Rochester, Minnesota. Dr. Okun is the director at Norman Fixel Institute for Neurological Diseases and distinguished professor of neurology at University of Florida in Gainesville, Florida. Additional Resources Read the issue: continuum.aan.com Subscribe to Continuum®: shop.lww.com/Continuum Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @LyellJ Guest: @MichaelOkun Full episode transcript available here: Dr Jones: Our ability to move through the world is one of the essential functions of our nervous system. Gross movements like walking ranging down to fine movements with our eyes and our hands, our ability to create and coordinate movement is something many of us take for granted. So what do we do when those movements stop working as we intend? Today I have the opportunity to speak with one of the world's leading experts on movement disorders, Dr Michael Okun, about the latest issue of Continuum on Movement Disorders. Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about subscribing to the journal, listening to verbatim recordings of the articles, and exclusive access to interviews not featured on the podcast. Dr Jones: This is Dr Lyle Jones, Editor-in-Chief of Continuum: Lifelong Learning in Neurology. Today, I'm interviewing Dr Michael Okun, who is Continuum's guest editor for our latest issue on movement disorders. Dr Okun is the Adelaide Lackner Distinguished Professor of Neurology at the University of Florida in Gainesville, where he's also the director of the Norman Fixel Institute for Neurological Diseases. Dr Okun, welcome, and thank you for joining us today. Why don't you introduce yourselves to our listeners?  Dr Okun: It's great to be here today. And I'm a neurologist. Everybody who knows me knows I'm pretty simple. I believe the patient's the sun and we should always orbit around the person with disease, and so that's how I look at my practice. And I know we always participate in a lot of research, and I've got a research lab and all those things. But to me, it's always the patients and the families first. So, it'll be great to have that discussion today.  Dr Jones: Yeah, thank you for that, Dr Oaken. Obviously, movement disorders is a huge part of our field of neurology. There are many highly prevalent conditions that fit into this category that most of our listeners will be familiar with: idiopathic Parkinson's disease, essential tremor, tic disorders and so on. And having worked with trainees for a long time, it's one of the areas that I see a lot of trainees gravitate to movement disorders. And I think it's in part because of the prevalence; I think it's in part because of the diversity of the specialty with treatment options and DBS and Botox. But it's also the centrality of the neurologic exam, right? That's- the clinical examination of the patient is so fundamental. And we'll cover a lot of topics today with some questions that I have for you about biomarkers and new developments in the field. But is that your sense too, that people are drawn to just the old-fashioned, essential focus on the neurologic encounter and the neurologic exam? Dr Okun: I believe that is one of the draws to the field of movement. I think that you have neurologists from all over the world that are really interested and fascinated with what things look like. And when you see something that's a little bit, you know, off the normal road or off the normal beaten path… and we are always curious. And so, I got into movement disorders, I think, accidentally; I think even as a child, I was looking at people who had abnormal movements and tremors and I was very fascinated as to why those things happened and what's going on in the brain. And, you know, what are the symptoms and the signs. And then later on, even as my own career developed, that black bag was so great as a neurologist. I mean, it makes us so much more powerful than any of the other clinicians---at least in my biased opinion---out on the wards and out in the clinic. And, you know, knowing the signs and the symptoms, knowing how to do a neurological examination and really walking through the phenomenology, what people look like, you know, which is different than the geno- you know, the genotypes, what the genes are. What people look like is so much more important as clinicians. And so, I think that movement disorders is just the specialty for that, at least in my opinion. Dr Jones: And it helps bring it back to the patient. And that's something that I saw coming through the articles in this issue. And let's get right to it. You've had a chance to review all these articles on all these different topics across the entire field of movement disorders. As you look at that survey of the field, Dr Okun, what do you think is the most exciting recent development for patients with movement disorders?  Dr Okun: I think that when you look across all of the different specialties, what you're seeing is a shift. And the shift is that, you know, a lot of people used to talk in our generation about neurology being one of these “diagnose and adios” specialties. You make the diagnosis and there's nothing that you can do, you know, about these diseases. And boy, that has changed. I mean, we have really blown it out of the water. And when you look at the topics and what people are writing about now and the Continuum issue, and we compare that the last several Continuum issues on movement disorders, we just keep accumulating a knowledge base about what these things look like and how we can treat them. And when we start thinking about, you know, all of the emergence of the autoimmune disorders and identifying the right one and getting something that's quite treatable. Back in my day, and in your day, Lyle, we saw these things and we didn't know what they were. And now we have antibodies, now we can identify them, we can pin them down, and we can treat many of them and really change people's lives. And so, I'm really impressed at what I see in changes in identification of autoimmune disorders, of channelopathies and some of the more rare things, but I'm also impressed with just the fundamental principles of how we're teaching people to be better clinicians in diseases like Parkinson's, Huntington's, ataxia, and Tourette. And so, my enthusiasm for this issue of Continuum is both on, you know, the cutting edge of what we're seeing based on the identification on our exams, what we can do for these people, but also the emergence of how we're shifting and providing much better care across a continuum for folks with basal ganglia diseases. Dr Jones: Yeah, I appreciate that perspective, Dr Okun. One of the common themes that I saw in the issue was with these new developments, right, when you have new tools like new diagnostic biomarker tools, is the question of if and when and how to integrate those into daily clinical practice, right? So, we've had imaging biomarkers for a while, DAT scans, etc. For patients with idiopathic Parkinson disease, one of the things that I hear a lot of discussion and controversy about are the seed amplification assays as diagnostic biomarkers. What can you tell us about those? Are those ready for routine clinical use yet?  Dr Okun: I think the main bottom-line point for folks that are out there trying to practice neurology, either in general clinics or even in specialty clinics, is to know that there is this movement toward, can we biologically classify a disease? One of the things that has, you know, really accelerated that effort has been the development of these seed amplification assays, which---in short for people who are listening---are basically, we “shake and bake” these things. You know? We shake them for like 20 hours and we use these prionlike proteins, and we learn from diseases like prion disease how to kind of tag these things and then see, do they have degenerative properties? And in the case of Parkinson's disease, we're able to do this with synuclein. That is the idea of a seed amplification assay. We're able to use this to see, hey, is there synuclein present or not in this sample? And people are looking at things like cerebrospinal fluid, they're looking at things like blood and saliva, and they're finding it. The challenge here is that, remember- and one of the things that's great about this issue of Continuum is, remember, there are a whole bunch of different synucleinopathies. So, Dr Jones, it isn't just Parkinson's disease. So, you've got Parkinson's disease, you've got Lewy body, you know, and dementia with Lewy bodies. You've got, you know, multiple system atrophy is within that synucleinopathy, you know, group primary autonomic failure… so not just Parkinson's disease. And so, I think we have to tap the brakes as clinicians and just say, we are where we are. We are moving in that direction. And remember that a seed amplification assay gives you some information, but it doesn't give you all the information. It doesn't forgive you looking at a person over time, examining them in your clinic, seeing how they progress, seeing their response to dopamine- and by the way, several of these genes that are associated with Parkinson; and there's, you know, less than 20% of Parkinson is genetic, but several of these genes, in a solid third---and in some cases, in some series, even more---miss the synuclein assay, misses, you know, the presence of a disease like Parkinson's disease. And so, we have to be careful in how we interpret it. And I think we're more likely to see over time a gemish: we're going to smush together all this information. We're going to get better with MRIs. And so, we're actually doing much better with MRIs and AI-based intelligence. We've got DAT scans, we've got synuclein assays. But more than anything, everybody listening out there, you can still examine the person and examine them over time and see how they do over time and see how they do with dopamine. And that is still a really, really solid way to do this. The synuclein assays are probably going to be ready for prime time more in choosing and enriching clinical trials populations first. And you know, we're probably 5, 10 years behind where Alzheimer's is right now. So, we'll get there at some point, but it's not going to be a silver bullet. I think we're looking at these are going to be things that are going to be interpreted in the context for a clinician of our examination and in the context of where the field is and what you're trying to use the information for. Dr Jones: Thank you for that. And I think that's the general gestalt I got from the articles and what I hear from my colleagues. And I think we've seen this in other domains of neurology, right? We have the specificity and sensitivity issues with the biomarkers, but we also have the high prevalence of copathology, right? People can have multiple different neurodegenerative problems, and I think it gets back to that clinical context, like you said, following the patient longitudinally. That was a theme that came out in the idiopathic Parkinson disease article. And while we're on Parkinson disease, you know, the first description of that was what, more than two hundred years ago. And I think we're still thinking about the pathophysiology of that disorder. We understand risk factors, and I think many of our listeners would be familiar with those. But as far as the actual cause, you know, there's been discussion in recent years about, is there a role of the gut microbiome? Is this a prionopathic disorder? What's your take on all of that?  Dr Okun: Yeah, so it's a great question. It's a super-hot area right now of Parkinson. And I kind of take this, you know, apart in a couple of different ways. First of all, when we think about Parkinson disease, we have to think upstream. Like, what are the cause and causes? Okay? So, Parkinson is not one disease, okay? And even within the genes, there's a bunch of different genes that cause it. But then we have to look and say, well, if that's less than 20% depending on who's counting, then 80% don't have a single piece of DNA that's closely associated with this syndrome. And so, what are we missing with environment and other factors? We need to understand not what happens at the end of the process, not necessarily when synuclein is clumping- and by the way, there's a lot of synuclein in the brains normally, and there's a lot of Tau in people's brains who have Parkinson as well. We don't know what we don't know, Dr Jones. And so when we begin to think about this disease, we've got to look upstream. We've got to start to think, where do things really start? Okay? We've got to stop looking at it as probably a single disease or disorder, and it's a circuit disorder. And then as we begin to develop and follow people along that pathway and continuum, we're going to realize that it's not a one-size-fits-all equation when we're trying to look at Parkinson. By the way, for people listening, we only spend two to three cents out of every dollar on prevention. Wouldn't prevention be the best cure, right? Like, if we were thinking about this disease. And so that's something that we should be, you know, thinking about. And then the other is the Global Burden of Disease study. You know, when we wrote about this in a book called Ending Parkinson's Disease, it looked like Parkinson's was going to double by 2035. The new numbers tell us it's almost double to the level that we expected in 2035 in this last series of numbers. So, it's actually growing much faster. We have to ask why? Why is it growing faster? And then we have lots of folks, and even within these issues here within Continuum, people are beginning to talk about maybe these environmental things that might be blind spots. Is it starting in our nose? Is it starting in our gut? And then we get to the gut question. And the gut question is, if we look at the microbiomes of people with Parkinson, there does seem to be, in a group of folks with Parkinson, a Parkinson microbiome. Not in everyone, but if you look at it in composite, there seems to be some clues there. We see changes in Lactobacillus, we see some bacteria going up that are good, some bacteria going down, you know, that are bad. And we see flipping around, and that can change as we put people on probiotics and we try to do fecal microbiota transplantations- which, by the way, the data so far has not been positive in Parkinson's. Doesn't mean we might not get there at some point, but I think the main point here is that as we move into the AI generation, there are just millions and millions and millions of organisms within your gut. And it's going to take more than just our eyes and just our regular arithmetic. You and I probably know how to do arithmetic really well, but this is, like, going to be a much bigger problem for computers that are way smarter than our brains to start to look and say, well, we see the bacteria is up here. That's a good bacteria, that's a good thing or it's down with this bacteria or this phage or there's a relationship or proportion that's changing. And so, we're not quite there. And so, I always tell people---and you know, we talk about the sum in the issue---microbiomes aren't quite ready for prime time yet. And so be careful, because you could tweak the system and you might actually end up worse than before you started. So, we don't know what we don't know on this issue.  Dr Jones: And that's a great point. And one of the themes they're reading between the lines is, we will continue to work on understanding the bio-pathophysiology, but we can't wait until that day to start managing the risk factors and treating patients, which I think is a good point. And if we pivot to treatment here a little bit, you know, one of the exciting areas of movement disorders---and really neurology broadly, I think movement disorders has led the field in many ways---is bioelectronic therapy, or what one of my colleagues taught me is “electroceutical therapy”, which I think is a wonderful term. Dr Okun, when our listeners are hearing about the latest in deep brain stimulation in patients who have movement disorders, what should they know? What are the latest developments in that area with devices? Dr Okun: Yeah. So, they should know that things are moving rapidly in the field of putting electricity into the brain. And we're way past the era where we thought putting a little bit of electricity was snake oil. We know we can actually drive these circuits, and we know that many of these disorders---and actually, probably all of the disorders within this issue of Continuum---are all circuit disorders. And so, you can drive the circuit by modulating the circuit. And it's turned out to be quite robust with therapies like deep brain stimulation. Now, we're seeing uses of deep brain stimulation across multiple of these disorders now. So, for example, you may think of it in Parkinson's disease, but now we're also seeing people use it to help in cases where you need to palliate very severe and bothersome chorea and Huntington's disease, we're seeing it move along in Tourette syndrome. We of course have seen this for various hyperkinetic disorders and dystonias. And so, the main thing for clinicians to realize when dealing with neuromodulation is, take a deep breath because it can be overwhelming. We have a lot of different devices in the marketplace and no matter how many different devices we have in the marketplace, the most important thing is that we get the leads. You know, where we're stimulating into the right location. It's like real estate: location, location, location, whether you've got a lead that can steer left, right, up, down and do all of these things. Second, if you're feeling overwhelmed because there are so many devices and so many settings, especially as we put these leads in and they have all sorts of different, you know, nodes on them and you can steer this way and that way, you are not alone. Everybody is feeling that way now. And we're beginning to see AI solutions to that that are going to merge together with imaging, and then we're moving toward an era of, you know, should I say things like robotic programming, where it's going to be actually so complicated as we move forward that we're going to have to automate these systems. There's no way to get this and scale this for all of the locales within the United States, but within the entire world of people that need these types of devices and these therapies. And so, it's moving rapidly. It's overwhelming. The most important thing is choosing the right person. Okay? For this, with multidisciplinary teams, getting the lead in the right place. And then all these other little bells and whistles, they're like sculpting. So, if you think of a sculpture, you kind of get that sculpture almost there. You know, those little adds are helping to maybe make the eyes come out a little more or the facial expression a little bit better. There's little bits of sculpting. But if you're feeling overwhelmed by it, everybody is. And then also remember that we're starting to move towards some trials here that are in their early stages. And a lot of times when we start, we need more failures to get to our successes. So, we're seeing trials of people looking at, like, oligo therapies and protein therapies. We're seeing CRISPR gene therapies in the laboratory. And we should have a zero tolerance for errors with CRISPR, okay? we still have issues with CRISPR in the laboratory and which ones we apply it to and with animals. But it's still pretty exciting when we're starting to see some of these therapies move forward. We're going to see gene therapies, and then the other thing we're going to see are nano-therapies. And remember, smaller can be better. It can slip across the blood brain barrier, you have very good surface area-to-volume ratios, and we can uncage drugs by shining things like focused ultrasound beams or magnets or heat onto these particles to turn them on or off. And so, we're seeing a great change in the field there. And then also, I should mention: pumps are coming and they're here. We're getting pumps like we have for diabetes and neurology. It's very exciting. It's going to be overwhelming as everybody tries to learn how to do this. So again, if you're feeling overwhelmed, so am I. Okay? But you know, pumps underneath the skin for dopamine, pumps underneath the skin for apomorphine. And that may apply to other disorders and not just Parkinson as we move along, what we put into those therapies. So, we're seeing that age come forward. And then making lesions from outside the brain with focused ultrasound, we're starting to get better at that. Precision is less coming from outside the brain; complications are also less. And as we learn how to do that better, that also can provide more options for folks. So, a lot of things to read about in this issue of Continuum and a lot of really interesting and beyond, I would say, you know, the horizon as to where we're headed.  Dr Jones: Thank you for that. And it is a lot. It can be overwhelming, which I guess is maybe a good reason to read the issue, right? I think that's a great place to end and encourage our listeners to pick up the issue. And Dr Okun, I want to thank you for joining us today. Thank you for such a great discussion on movement disorders. I learned a lot. I'm sure our listeners will as well, given the importance of the topic, your leadership in the field over many years. I'm grateful that you have put this issue together. So, thank you. And you're a busy person. I don't know how we talked you into doing this, but I'm really glad that we did.  Dr Okun: Well, it's been my honor. And I just want to point out that the whole authorship panel that agreed to write these articles, they did all the work. I'm just a talking head here, you know, telling you what they did, but they're writing, and the people that are in the field are really, you know, leading and helping us to understand, and have really put it together in a way that's kind of helped us to be better clinicians and to impact more lives. So, I want to thank the group of authors, and thank you, Dr Jones. Dr Jones: Again, we've been speaking with Dr Michael Okun, guest editor of Continuum's most recent issue on movement disorders. Please check it out. And thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. Thank you for listening to Continuum Audio.

Joe Skipper sits down for his first ever episode hosting his own podcast on The Triathlon Hour and for the occasion he's joined by the superstar Taylor Knibb. Joe & Taylor have a conversation that makes you feel like you're sitting back on a couch around the fire with them after a day on training camp and just listening to them both share stories and have a laugh. Whether you're out training while you listening, driving your car, on the couch having a warm beverage or doing some housework you'll definitely love this one.  Nord VPN: Take advantage of a great deal with Nord VPN use the code triathlonhour or visit  nordvpn.com/triathlonhour to get a huge discount in the 2 year plans PLUS 4 extra months! It is risk free with Nord's 30 days money back guarantee!  Precision: Use the code TTH25 to get 15% off your first order with Precision at Precision Fuel & Hydration or subscribe to the Patreon and access the link that will save you 20% on every order, not just your first Patreon Pillar: Use the code TTH to get 15% off your first order with Pillar Performance at Pillar Performance or use The Feed for North American customers Patreon: We put a lot of time & energy into bringing you this podcast every week and have done for 4 years now. If you appreciate what we do, we would love your support and you can do so for less than the cost of a coffee per week on Patreon  - Patreon link

What if medicine worked to get you healthier overall—not just people like you or for one or another symptom? In the latest episode of TGen Talks, host Karie Dozer sits down with Nicholas Schork, Ph.D., and Laura Goetz, M.D., co-authors of a recent commentary published in Nature Communications, From Precision Interventions to Precision Health, to explore the promise—and complexity—of truly personalized healthcare. Traditional medicine treats symptoms. Precision healthcare, however, rethinks that model entirely. By tapping into genomics, environment, lifestyle, and even real-time data from wearable devices, Drs. Schork and Goetz discuss developing highly individualized approaches that don't just treat illness—they aim to prevent it. Together, they unpack how this shift could redefine everything from how drugs are tested, to how diseases are managed, and even how we define “health.” They discuss cutting-edge innovations like anti-sense oligonucleotides—drugs custom-made for an individual's genetic code—and the rise of geroprotectors, compounds designed to support whole-body wellness as we age. They discuss the difficulties of such specific treatments and the differences in the way different patients might metabolize and respond to the same medicine. The future of medicine isn't one-size-fits-all. It's N-of-1—and it might just be closer than you think.

Host(s): Dr. Mary Goldberg, Co-Director of the IMPACT Center at the University of PittsburghGuest(s): Student Design Team - HAT, University of California, Berkeley: Yuka Fan, Emily Boeschoten, Adria Gonzalez, Sasha PortnovaIMPACT Center | Website, Facebook, LinkedIn, Twitter HAT Team Information | Video, Website, PublicationTranscript | Word Doc,  PDF Discussion TopicsIntro & Episode OverviewTeam Formation and BackgroundsClinical Motivation Behind HATHow HAT WorksTech Design Choices (Leap vs Webcam)Reliability Testing InsightsInclusivity and Accessibility in DesignOT Perspective on Disability RepresentationClosing & Teaser for Part 2

Cautious Clay is the stage name of singer, multi-instrumentalist and songwriter Josh Karpeh. He burst out of the gate with his song “Cold War” in 2017, a song that was later sampled by Taylor Swift in her track “London Boy”.  Cautious Clay's music blends R&B, neo-soul, jazz, and more, and his subsequent output includes cowriting with John Legend and of course his own records, the most recent of which is called The Hours: Morning.  Cautious Clay and his band play new music, in-studio. Set list: 1. Fade Blue 2. Tokyo Lift (5am) 3. Art MuseumThe Hours: Morning by Cautious Clay

In this episode of the show, I'm joined by Shawn Melanson — a Jiu-Jitsu black belt, highly respected instructor, and the owner of Precision Jiu Jitsu in New Hampshire. Known for his incredibly refined and effective teaching style, Shawn is a coach's coach — a technician with a deep understanding of wrestling for BJJ integration and a powerful advocate for intelligent grappling.Shawn has become a go-to resource on BJJ Fanatics, where his instructional series, such as Precision Wrestling for Jiu Jitsu and Precision Attacks and Sweeps from Butterfly, Half, and Knee Shield, have helped practitioners around the world elevate their game. In this conversation, we talk about the evolution of his style, how wrestling has shaped his Jiu-Jitsu, his approach to coaching, and what it means to develop high-percentage techniques that hold up under pressure. We also dive into training culture, competition prep, and modern grappling.Links:https://www.instagram.com/shawnmelanson160/https://precisionjiujitsunh.com/https://bjjfanatics.com/collections/instructional-videos/fighter_shawn-melanson?list=1Salt Electrolytes use code FWB for 15% off. https://saltelectrolytes.com/?fwb Become a VIP member for only .99 a month, get ad free, uncensored, early episodes podcasters.spotify.com/pod/show/foreverwhitebelt/subscribe@foreverwhitebeltshow.Go buy your Forever White Belt merchandise at teespring.com/forever-white-belthttps://linktr.ee/foreverwhitebelt#brazilianjiujitsu #jiujitsu #grappling #bjj #nogi

This week we talk about: Zia Agents Release Updates Zoho Projects: Custom Business Calendars Zoho Books: Blueprints for Custom Modules Our Implementation, Read, Code Share, and Tip of the Week Read the show notes: https://zenatta.com/episode-365/   

Dr. George Sledge, Executive VP and Chief Medical Officer of Caris Life Sciences, is using advanced molecular testing, including DNA, RNA, and protein analysis, to identify specific mutations and characteristics of a patient's tumor, allowing for more personalized and targeted treatment. The company is developing liquid biopsies to detect cancer early, identify minimal residual disease, and assess the potential for future cancer development. Caris has a database of over half a million patients whose tumors have undergone next-generation sequencing, allowing them to draw increasingly accurate conclusions. The future of precision oncology is expected to involve broader and earlier use of next-generation sequencing as the cost of the test continues to decrease significantly. George explains, "Caris Life Sciences is a molecular diagnostics company. Patients and their physicians send us tumor samples that can be obtained either from the primary tissue or from a distant recurrent site. When they come to us, we do several things. We look at DNA, what's called whole exome. We look at RNA, what's called whole transcriptome. We also frequently look at the protein level at immunohistochemistry, looking at slides that have been stained to look for particular molecular lesions that may be important from a treatment standpoint. Based on all of these, we're able to provide patients with information about which drugs represent the most appropriate treatment for their disease. This, of course, allows you to go to a drug that hopefully will be less toxic and more effective for your particular disease."  "When we look at the very specific mutations that manifest themselves at the level of either DNA or RNA, this requires fairly high technology, what's called next-generation sequencing, which allows us to pick up all these individual mutations that make up a particular patient's cancer. And every patient's cancer is different. Every patient's cancer involves different combinations of mutations that result in different responses to different treatments." #CarisLifeSciences #CancerResearch #PrecisionMedicine #RealWorldData #AccestoCare #HealthEquity #NextGenerationSequencing #NGS #LiquidBiopsy #ClinicoGenomic #Biomarkers #PanCancer carislifesciences.com Listen to the podcast here

Dr. George Sledge, Executive VP and Chief Medical Officer of Caris Life Sciences, is using advanced molecular testing, including DNA, RNA, and protein analysis, to identify specific mutations and characteristics of a patient's tumor, allowing for more personalized and targeted treatment. The company is developing liquid biopsies to detect cancer early, identify minimal residual disease, and assess the potential for future cancer development. Caris has a database of over half a million patients whose tumors have undergone next-generation sequencing, allowing them to draw increasingly accurate conclusions. The future of precision oncology is expected to involve broader and earlier use of next-generation sequencing as the cost of the test continues to decrease significantly. George explains, "Caris Life Sciences is a molecular diagnostics company. Patients and their physicians send us tumor samples that can be obtained either from the primary tissue or from a distant recurrent site. When they come to us, we do several things. We look at DNA, what's called whole exome. We look at RNA, what's called whole transcriptome. We also frequently look at the protein level at immunohistochemistry, looking at slides that have been stained to look for particular molecular lesions that may be important from a treatment standpoint. Based on all of these, we're able to provide patients with information about which drugs represent the most appropriate treatment for their disease. This, of course, allows you to go to a drug that hopefully will be less toxic and more effective for your particular disease."  "When we look at the very specific mutations that manifest themselves at the level of either DNA or RNA, this requires fairly high technology, what's called next-generation sequencing, which allows us to pick up all these individual mutations that make up a particular patient's cancer. And every patient's cancer is different. Every patient's cancer involves different combinations of mutations that result in different responses to different treatments." #CarisLifeSciences #CancerResearch #PrecisionMedicine #RealWorldData #AccestoCare #HealthEquity #NextGenerationSequencing #NGS #LiquidBiopsy #ClinicoGenomic #Biomarkers #PanCancer carislifesciences.com Download the transcript here

Join us on the ERCM Medicine Podcast for a conversation with John R. Adler Jr., MD, the visionary inventor of the CyberKnife and founder of Zap-X. As a Stanford professor, Dr. Adler has revolutionized neurosurgery through the development of robotic radiosurgery systems.He shares his extraordinary journey – from being inspired by Lars Leksell at the Karolinska Institute in Stockholm to founding two groundbreaking medical technology companies. He speaks candidly about daily setbacks, the skepticism of colleagues (who initially called the CyberKnife „Adler's Folly“), and why persistence is the key to success.His provocative message to young innovators: „Don't do it – unless you're prepared to never give up.“ This episode provides an honest assessment of the challenges in translating medical innovations into clinical practice.Key Topics:Innovation vs. Reality: Why most inventions failCyberKnife Development: From initial idea to market successRadiosurgery as a surgical tool: Precision without cuttingZapX: The next generation of specialized radiosurgeryMedical resistance: Why some neurosurgeons resist modern technologiesDer ERCM Medizin Podcast – Social & Website:Instagram: @ercm.podcastTikTok: @ercm.podcastWebsite: www.erc-munich.comContact: podcast@erc-munich.comJohn R. Adler Jr., MD:Website: https://zapsurgical.com/About: https://en.wikipedia.org/wiki/John_R._Adler LinkedIn: https://www.linkedin.com/in/john-adler-1875b95/Timestamps:00:00 - Intro02:19 - From Karolinska fellowship to the CyberKnife idea04:46 - The biggest hurdles in the early years06:31 - Persisting despite daily setbacks08:12 - From academic to entrepreneur10:18 - CyberKnife success wasn't enough: The ZapX vision13:37 - Radiosurgery as a neurosurgical tool16:18 - Resistance in the neurosurgery community18:09 - Advice for young innovators: "Don't do it"20:04 - Legacy and unfinished work21:58 - The future of radiosurgery#CyberKnife #Radiosurgery #MedicalInnovation #Neurosurgery #JohnAdler #Entrepreneur #interview #StanfordMedicine #ZapX #ercmpodcast

USDA Farm Production undersecretary nominee Richard Fordyce agreed at his Senate confirmation hearing to tackle key issues that directly impact producers.

In this episode of Plastic Surgery Untold, Dr. Franco breaks down one of the biggest questions patients have when planning a breast augmentation or implant exchange: Where should your breast implants go? Placement options like under the muscle, above the muscle, or subfascial have come a long way as implant technology and surgical techniques improve. Dr. Franco explains how your unique anatomy, the type of implant you choose, and your goals for shape, cleavage, and feel all play a role in finding the best option for you. From older saline implants to today's highly cohesive gels, knowing the differences can help you get a natural result and protect your natural muscle and tissue. Key topics covered: How under the muscle, dual plane, and subfascial placement each affect cleavage, shape, animation deformity, and recovery time Why newer implants and cohesive gels have changed what's possible and why more patients are considering above the muscle placement The role of the pec major muscle, natural ligaments, and internal bras to support your results and help with rippling or implant show What to know about breast preservation techniques and next-generation implants that are on the way in 2026 This episode will help you ask the right questions and understand the real pros and cons so you and your surgeon can choose what works best for your body and your goals. See the anatomy visuals and hear the full breakdown on YouTube. Plastic Surgery Untold, greatest podcast in the world as voted by us!  

Portland Public Schools' new board is facing an uphill battle, local farms are grappling with potential new restrictions, and Gov. Tina Kotek is proposing a new financial strategy to keep ODOT afloat. Joining host Claudia Meza for the Friday news round-up are Willamette Week reporter and author, Brianna Wheeler, and our executive producer, John Notarianni. Discussed in Today's Episode: Claudia Meza Brings Humor and Precision to City Cast Podcast [Willamette Week] At Portland Public Schools, a ‘Mom Takeover' and a Brewing Storm [Oregonian

Kate Shaw is trusting the process — the bioprocess. The Auburn senior took that sweet Pathway to the Plains to pursue the ever versatile bioprocess engineering degree. And, as you'll find out, that one decision has led to a lot precision. 

Joe Skipper joins us to make a big announcement. Then we talk about Challenge Roth's Race Ranger data being released, lots of training chat as usual and is Joe being coached by Tadej Pogacar's coach? Listen in!!!  Nord VPN: Take advantage of a great deal with Nord VPN use the code triathlonhour or visit  nordvpn.com/triathlonhour to get a huge discount in the 2 year plans PLUS 4 extra months! It is risk free with Nord's 30 days money back guarantee!  Precision: Use the code TTH25 to get 15% off your first order with Precision at Precision Fuel & Hydration or subscribe to the Patreon and access the link that will save you 20% on every order, not just your first Patreon Pillar: Use the code TTH to get 15% off your first order with Pillar Performance at Pillar Performance or use The Feed for North American customers Patreon: We put a lot of time & energy into bringing you this podcast every week and have done for 4 years now. If you appreciate what we do, we would love your support and you can do so for less than the cost of a coffee per week on Patreon  - Patreon link

They want us to believe that silence is strength. That if we keep our heads down, the storm will pass. But we are the storm. And our storm doesn't need fists. It needs strategy, courage, and the fire of militant nonviolence. In the latest episode of Gaslit Nation, Jamila Raqib, the executive director of the Albert Einstein Institution, delivers a masterclass in radical defiance without a single weapon raised. Raqib doesn't just talk resistance. She teaches the art of war, the nonviolent kind, built on discipline, planning, and unshakeable conviction. She carries forward the torch of Gene Sharp, the quiet revolutionary whose writings, like From Dictatorship to Democracy, which the Gaslit Nation Book Club read in March, have armed movements from Serbia to Syria. His ideas are dangerous, not because they incite chaos, but because they illuminate how to take power back without bloodshed. And dictators fear that more than any rifle. This is militant nonviolence. It's strategic. It's disruptive. And when practiced with precision, it brings regimes to their knees. Blueprint for the Battle Ahead Raqib outlines a crucial truth: power is not monolithic. It comes from the obedience of people, workers, civil servants, police, students. Withdraw that obedience, and even the strongest tyrant collapses. Take Serbia. Take Bangladesh. The world keeps giving us proof that nonviolent action isn't weak; it's lethal to authoritarianism when wielded with discipline. These movements succeeded not because they were polite, but because they were strategic. Organized. Defiant. This is how repression backfires. Every crackdown becomes fuel. Every jail cell, every bullet, every propaganda campaign becomes a rallying cry, if activists know how to use it. Weapons of the Peaceful Warrior Raqib reminds us that art is a weapon. Culture is armor. Community is infrastructure. And technology is a battlefield. Whether it empowers or undermines you depends on how well you understand it. Movements rise and fall on logistics, not just slogans. Fear will always be there. That's normal. But as Raqib insists, fear doesn't mean stop. It means go smart. Fear is a compass, if it scares the regime, you're probably doing something right. Nonviolence is Not Passive. It's Precision. This conversation isn't about kumbaya. It's about battle-readiness. It's about studying the terrain of power, exploiting the cracks, and toppling giants with the slow, grinding force of disciplined resistance. Nonviolence doesn't mean surrender. It means refusing to give your enemy the war they want. It means winning on your terms. And in a time of rising fascism, digital surveillance, and global despair, we must turn to the tools that have worked, again and again. So study Gene Sharp. Listen to Raqib. Organize like your life depends on it, because it does. This is not the time for feel-good hashtags. This is the time for public education, mass mobilization, and strategic action. Nonviolent resistance is not soft. It's the hardest fight there is. But it's the one that wins. EVENTS AT GASLIT NATION: NEW DATE! Thursday July 31 4pm ET – the Gaslit Nation Book Club discusses Antoine de Saint Exupéry's The Little Prince written in the U.S. during America First.  Minnesota Signal group for Gaslit Nation listeners in the state to find each other, available on Patreon.  Vermont Signal group for Gaslit Nation listeners in the state to find each other, available on Patreon.  Arizona-based listeners launched a Signal group for others in the state to connect, available on Patreon.  Indiana-based listeners launched a Signal group for others in the state to join, available on Patreon.  Florida-based listeners are going strong meeting in person. Be sure to join their Signal group, available on Patreon.  Have you taken Gaslit Nation's HyperNormalization Survey Yet? Gaslit Nation Salons take place Mondays 4pm ET over Zoom and the first ~40 minutes are recorded and shared on Patreon.com/Gaslit for our community Want to enjoy Gaslit Nation ad-free? Join our community of listeners for bonus shows, exclusive Q&A sessions, our group chat, invites to live events like our Monday political salons at 4pm ET over Zoom, and more! Sign up at Patreon.com/Gaslit!

From prison to forever, this is a love story like no other! Meet Lando and Carrie, a couple who defied the odds to build a powerful bond rooted in redemption, faith, and unbreakable commitment. Their journey began in the unlikeliest of places—a prison visiting room—and evolved into a 27-year marriage filled with challenges, triumphs, and unwavering love. They share how friendship, faith, and intentionality became the foundation of their relationship, proving that second chances can lead to extraordinary outcomes. Prepare to be inspired by their testimony of resilience, grace, and enduring love. Watch now to discover how they turned adversity into a beautiful forever! PART 2 Support the Mathews and visit lcmcontructiionservices.com and 203konline.com Create PEACE in your marriage by getting CRAZY at MarriedIntoCrazy.com  #lovebeyondwalls #overcomingadversity #relationshipresilience #personalgrowth #lovestrategies  CHAPTERS: 00:00 - Intro 00:54 - How Carrie and Lando Met 06:36 - Carrie and Lando's First Date 10:25 - Lando's Surprise: Carrie's Jail Visit 14:07 - Tipping Point in Relationships 18:55 - Building with Precision, Delivering with Pride 22:40 - Pillars of a Strong Marriage 26:30 - Importance of Friendship in Marriage 30:10 - Importance of Adversity in Relationships 32:40 - Turning Point in Their Relationship 34:24 - Overcoming Adversity Together 38:30 - The Power of Surrender 42:27 - Strategies for Overcoming Adversity 44:53 - How to Reach the Ministry 46:10 - The Need for Marriage Ministry 48:00 - Upcoming Ministry Plans and Initiatives 49:20 - Resources for the Formerly Incarcerated 50:03 - Future Plans for Prison and Jail Ministry

The Rib Revolution Is Here On the latest episode of Plastic Surgery Untold, we're diving into one of 2025's most buzzed-about procedures — RibX. This isn't your average waist contouring. Rib remodeling, also known as RibX, helps patients who want that snatched, fit silhouette without looking overfilled or overdone. It's an innovative approach that allows us to reshape the rib cage for enhanced curves — especially for patients who are naturally lean, have had a prior BBL, or simply want to refine their shape further. With body contouring shifting toward shape over size, RibX is changing what's possible. What makes RibX revolutionary: Precision-guided with ultrasound for safe, accurate reshaping Tiny incision — smaller than a pinky Ideal for lean patients, failed BBLs, or combo procedures Great when paired with liposculpting, fat transfer, or AlloClae Post-op corset locks in long-term results Offers structure and flow from waist to hips to butt This episode breaks it all down — from the history of rib aesthetics to the step-by-step surgical process and post-op care. Whether you're starting your transformation or revisiting a past procedure, RibX could be the key to your dream silhouette. Watch the full episode now on YouTube or wherever you stream your favorite podcasts.

It sounds counter intuitive, especially in a world where we are obsessed with speed and suffering the idea that your coffee shop spin could be making you a better rider sounds crazy. But in this episode Anthony is going to break down why going slow to go fast is not just a catch phrase, it's backed by science and is trusted by the worlds top coaches. Surfshark - Online security starts with a VPN and I trust Surfshark. Go to⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://surfshark.com/roadman⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ and use code roadman at checkout to get 4 extra months of Surfshark VPN.NOMIO is clinically proven to:Lower lactate levels, Reduce oxidative stress, Improve training adaptations And deliver a noticeable boost from the very first dose. Go to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.drinknomio.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ and check out this game changing supplement. 4iiiiReady to elevate your cycling game? Trust the 4iiii PRECISION 3+ Powermeter—precision, performance, and peace of mind, all in one.Learn more by visiting http://www.4iiii.comBIKMO Whether it's theft, damage, crashes, racing or travel, Bikmo's got your back. Their in-house claims team makes the process fast and painless, and here's the kicker — with 50% off multi-bike cover, you can protect all your bikes, and even your family's or mates' bikes, under one simple policy.Make sure you're covered - check the details in your policy docs. T&Cs apply.Head over to https://bikmo.com/uk/ and use the code ROADMAN to get covered & save money.

Slow is smooth, smooth is fast — the strength of Deliberative thinking

In this episode, Mark Ledlow is joined by Jennifer Laurence, an Estate Management Consultant in Private UHNW Service, and a Founder and President of Luxury Lifestyle Logistics. They discuss her role in estate management consultancy, focusing on operational logistics, standard procedures, and family management for high-net-worth individuals. Jennifer shares her insights into personalized service, the nuances of security for the ultra-wealthy, and the importance of protecting every aspect of a client's lifestyle. They also dive into Jennifer's passion for archery and how it serves as her personal therapy. Mark and Jennifer further delve into the critical need for risk assessment and the subtle complexities of maintaining privacy and security in the lives of affluent families.Learn about all this and more in this episode of The Fearless Mindset Podcast.KEY TAKEAWAYSEstate management for high-net-worth individuals requires personalized, holistic solutions beyond standard hospitality. Security is a spectrum: risk assessments and tailored strategies are essential for each client's unique profile. Privacy and confidentiality are major concerns for both clients and staff in luxury estate management. Every data point—utility bills, car titles, reservations—can be a vulnerability for high-profile individuals. The “circle of trust” must be carefully managed to balance service and privacy.QUOTES“We're serving individuals in their homes, and it's a very close, personable working relationship.” “Security risk is a spectrum. You have to understand what you can do internally, externally, and when it's right to bring in somebody full-time.” “Every single data point that you put your name on is ultimately a weak point for threat mitigation.” “You don't get to make your dinner reservations in your last name anymore. The world is too rich in data.” “Protective intelligence—that's the new era of security.”Get to know more about Jennifer Laurence through the links below.https://www.linkedin.com/in/jenniferlaurence/To hear more episodes of The Fearless Mindset podcast, you can go to https://the-fearless-mindset.simplecast.com/ or listen to major podcasting platforms such as Apple, Google Podcasts, Spotify, etc. You can also subscribe to the Fearless Mindset YouTube Channel to watch episodes on video.

Could your immune system hold the key to fighting cancer and slowing aging? Dr. Jeff Gross, expert in regenerative medicine and cellular therapies, joins host Dr. Scott A. Johnson to discuss how activated NK (Natural Killer) cell-derived exosomes are reshaping the future of medicine. Unlike traditional chemotherapy or radiation, NK cell exosome therapy offers targeted, non-toxic treatment by unleashing the body's innate ability to recognize and destroy cancer cells. You'll learn how these powerful biological agents work, why they diminish over time, and how "off-the-shelf" solutions could bring life-extending benefits to more people. This episode is a must-listen for anyone interested in cancer prevention, immunotherapy, and living longer—stronger.Connect with Dr. Scott A. Johnsonauthorscott.comFacebookInstagramYouTubeLinks to purchase booksConnect with Dr. Jeff GrossReCELLebrate.comInstagramTikTokYouTubeLinkedInTakeawaysCancer is a leading cause of death globally.Natural killer cells play a crucial role in our immune defense.Exosomes are signaling particles that help target abnormal cells.NK cell exosomes can potentially treat cancer without side effects.The presence of senescent cells correlates with biological aging.NK cell exosomes can be used preventively for high-risk individuals.Off-the-shelf NK exosomes simplify treatment processes.Immunotherapy encompasses various methods, including vaccines and antibodies.Reducing senescent cells can enhance health span and longevity.Essential oils may synergize with exosome therapies for enhanced effects.Chapters00:00Introduction to Cancer and Innovative Treatments05:25Understanding Natural Killer Cell Exosomes09:56Comparing NK Cell Exosomes to Traditional Therapies14:25Preventive Applications of NK Cell Exosomes18:59Case Studies and Patient Outcomes23:23The Intersection of Essential Oils and Exosomes24:45Short Outro.m4v

In this engaging episode of the Soul Seekers Podcast, host Johnny Mack reconnects with his longtime friend Jeff Winslow, an ... Read more The post Ep. 329 | Chasing Precision: Elevating Your Hunting Game through Competitive Shooting with Jeff Winslow appeared first on Soul Seekers.

In this episode Anthony talks about the ways in which newbie cyclists (& more experienced riders) fail to improve and what yu can do about it. Surfshark - Online security starts with a VPN and I trust Surfshark. Go to⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://surfshark.com/roadman⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ and use code roadman at checkout to get 4 extra months of Surfshark VPN.NOMIO is clinically proven to:Lower lactate levels, Reduce oxidative stress, Improve training adaptations And deliver a noticeable boost from the very first dose. Go to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.drinknomio.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ and check out this game changing supplement. 4iiiiReady to elevate your cycling game? Trust the 4iiii PRECISION 3+ Powermeter—precision, performance, and peace of mind, all in one.Learn more by visiting http://www.4iiii.comBIKMO Whether it's theft, damage, crashes, racing or travel, Bikmo's got your back. Their in-house claims team makes the process fast and painless, and here's the kicker — with 50% off multi-bike cover, you can protect all your bikes, and even your family's or mates' bikes, under one simple policy.Make sure you're covered - check the details in your policy docs. T&Cs apply.Head over to https://bikmo.com/uk/ and use the code ROADMAN to get covered & save money.REAPCustom Carbon Composition Bikes made in the UK. REAP's gravel bike is set to redefine gravel riding with 50mm+ tyre clearance https://reapbikes.com/

This week we talk about: Zoho Projects: Q2 2025 Updates Zoho Show: Zia AI Added Zoho WorkDrive: Zia Hubs Our Implementation, Read, Code Share, and Tip of the Week Read the show notes: https://zenatta.com/episode-364/   

On this episode of the Army Spotligh series, Kyle chats with none other than the king of sass, the host of the second longest running Warmachine podcast, the Bright Blinger himself, Ryan. They discuss all things Shadowflame Shard. Please enjoy and don't forget to send us your feedback!

Text us a pool question!Here's what we do differently when the pool water temp is up!!! In this episode of the Talking Pools podcast, Rudy Stankowitz delves into a chilling true crime story intertwined with the pool industry from his book, Blades of Glass available on Amazon.com.  The conversation shifts to industry insights, discussing recent trends and challenges in pool maintenance, particularly focusing on the chemistry of hot water and the complexities of testing in elevated temperatures. The episode concludes with practical advice for pool professionals on managing chemical balance in hot pools, emphasizing the importance of precision and understanding in maintaining pool health.takeawaysThis episode is not about typical pool maintenance tips.The story involves a shocking crime scene with stolen blood.Pools can be silent witnesses to both joy and tragedy.Hot water chemistry requires careful management.Testing in hot water can lead to inaccurate results.Chlorine behaves differently in high temperatures.Maintaining pools in hot weather is a unique challenge.Understanding chemistry is crucial for pool professionals.The importance of circulation in hot pools cannot be overstated.Precision in pool maintenance is key to preventing disasters.Sound Bites"This is not your usual pool pump repair story.""A refrigerator full of stolen blood.""Don't be that pool guy."Chapters00:00Diving into Darkness: A True Crime Crossover02:13The Crime Scene: Blood and Pools03:53The Aftermath: Unraveling the Mystery05:55The Pool as a Silent Witness15:32Industry Insights: Pool and Spa News24:20Hot Water: Managing Chemistry in Pools30:21Understanding Chlorine Behavior in Hot Water34:35Impact of Temperature on Water Testing40:10Chemical Management in High Temperatures46:24Hydraulic Efficiency and Pool Circulation50:56Managing Hot Pools: A Delicate Balance Support the showThank you so much for listening! You can find us on social media: Facebook Instagram Tik Tok Email us: talkingpools@gmail.com

Welcome back to the Superhumanize Podcast. Today, we step into the radiant realm of healing, where ancient light meets modern science. My guest is Forrest Smith, a visionary at the intersection of wellness innovation and technology.As the founder of Kineon Labs and a former extreme athlete, Forrest brings decades of insight, both as a high-performing human and as a pioneering entrepreneur. His journey spans continents, from the rugby fields of South China to the tech corridors of North America. Along the way, he has built and sold multiple companies, delved deep into Chinese medicine and philosophy, and emerged with a powerful mission: to make cutting-edge red light therapy accessible, effective, and rooted in science.In this conversation, we explore what makes red light such potent allies for recovery, inflammation, performance, and even emotional well-being. We discuss photobiomodulation, how light interacts with our tissues at the molecular level, and why precise dosing truly matters. We also touch on the exciting future of light therapy for brain health, mood support, and energy optimization.Whether you are curious about pain management without pharmaceuticals, or interested in how light can nourish and heal the body, this episode will light the path.Episode highlights:02:00 – Forrest's journey from China-based tech entrepreneur and extreme athlete to mission-driven wellness innovator.04:00 – The founding vision of Kineon Labs: making high-quality red light and laser therapy devices accessible for home use.05:00 – Explanation of red light therapy and photobiomodulation—how light interacts with the body at a molecular level.07:00 – Why precise dosing matters: understanding the biphasic dose curve and photon absorption.09:00 – The role of nitric oxide and hemoglobin in increasing oxygen delivery and blood flow through light exposure.10:30 – How light affects mitochondrial function, oxidative stress, and inflammation on a cellular level.13:00 – Use of red light therapy in stroke recovery: extending the life of cells deprived of oxygen.14:00 – Designing devices backwards from desired biological outcomes instead of product features.17:00 – Why lasers outperform LEDs for dosing depth and precision.19:30 – Real-world outcomes from Kineon's Move+ device: high performance athletes, military, and aging populations.21:00 – Sustainable pain relief and mobility improvements for osteoarthritis and chronic injuries.24:00 – Long-term cardiovascular effects of untreated joint injuries—and how light therapy reverses them.27:00 – The power of stacking light therapy with stem cells, PRP, and shockwave treatments.31:00 – Protocols for joint pain and recovery: knees, backs, and sprains.39:00 – Forrest's favorite protocol: “Proximal Priority Therapy” for systemic inflammation and mood enhancement.41:00 – Transcranial light therapy and its promise for brain health, neurotransmitter balance, and immune resilience.44:00 – Future innovations: EEG and vagus nerve stimulation to support PTSD and autonomic regulation.50:00 – What's next: real-time brain energy mapping with single photon avalanche diodes.51:00 – Where to find Kineon products and community resources.Resources mentioned:Kineon Labs website – https://kineon.ioMove+ wearable...

Why do cyclists shave their legs? For decades, we've been told it's for speed — Specialized even claimed it saves 79 seconds over 40km. But what if that science is flawed? In this video, we dig into the real reasons behind cycling's most iconic (and weirdest) ritual — from old-school tradition to group ride psychology. With insights from wind tunnel studies, Olympic bike designers, and pro riders like Alex Howes and Primož Roglič, we uncover why smooth legs became the ultimate badge of belonging in the peloton. It's about more than watts — it's about identity, trust, and culture. If you've ever wondered whether you should shave, this is the deep dive you didn't know you needed.Surfshark - Online security starts with a VPN and I trust Surfshark. Go to⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://surfshark.com/roadman⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ and use code roadman at checkout to get 4 extra months of Surfshark VPN.NOMIO is clinically proven to:Lower lactate levels, Reduce oxidative stress, Improve training adaptations And deliver a noticeable boost from the very first dose. Go to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.drinknomio.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ and check out this game changing supplement. 4iiiiReady to elevate your cycling game? Trust the 4iiii PRECISION 3+ Powermeter—precision, performance, and peace of mind, all in one.Learn more by visiting http://www.4iiii.comBIKMO Whether it's theft, damage, crashes, racing or travel, Bikmo's got your back. Their in-house claims team makes the process fast and painless, and here's the kicker — with 50% off multi-bike cover, you can protect all your bikes, and even your family's or mates' bikes, under one simple policy.Make sure you're covered - check the details in your policy docs. T&Cs apply.Head over to https://bikmo.com/uk/ and use the code ROADMAN to get covered & save money.REAPCustom Carbon Composition Bikes made in the UK. REAP's gravel bike is set to redefine gravel riding with 50mm+ tyre clearance https://reapbikes.com/

Are you up to date with management of patients with NTRK fusion-positive thyroid cancer? Credit available for this activity expires: 7/14/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002660?ecd=bdc_podcast_libsyn_mscpedu

This week in The War Room, Carson Rich, Eric Dunavant, Drew Brown, and Kristina Schuler dive into what's really happening behind the headlines—from AI-driven market moves to new crypto tax proposals, the return of tariffs, and what the “Big Beautiful Bill” could mean for your wallet.

In our next installment, we welcome Anne Reinke, the President & CEO of Intermodal Association of North America (IANA). For the past 20 years, Anne has helped navigate corporate, transportation policy & political experience throughout the supply chain. Not only did Anne serve as the President & CEO of the Transportation Intermediaries Association (TIA), but she's held senior roles at both USDOT AND CSX. From one lawyer to another, I am excited for this conversation. Let's go!Special thanks to Olive Garden's Never-Ending Soup, Salad & Breadsticks. This program is brought to you by DAT Freight & Analytics. Since 1978, DAT has helped truckers & brokers discover more available loads. Whether you're heading home or looking for your next adventure, DAT is building the most trusted marketplace in freight. New users of DAT can save 10% off for the first 12 months by following the link below. Built on the latest technology, DAT One gives you control over every aspect of moving freight, so that you can run your business with speed & efficiency. This program is also brought to you by our newest sponsor, GenLogs. GenLogs is setting a new standard of care for freight intelligence. Book your demo for GenLogs today at www.genlogs.io today!

From prison to forever, this is a love story like no other! Meet Lando and Carrie, a couple who defied the odds to build a powerful bond rooted in redemption, faith, and unbreakable commitment. Their journey began in the unlikeliest of places—a prison visiting room—and evolved into a 27-year marriage filled with challenges, triumphs, and unwavering love. They share how friendship, faith, and intentionality became the foundation of their relationship, proving that second chances can lead to extraordinary outcomes. Prepare to be inspired by their testimony of resilience, grace, and enduring love. Watch now to discover how they turned adversity into a beautiful forever! PART 1 Support the Mathews and visit lcmcontructiionservices.com and 203konline.com  Create PEACE in your marriage by getting CRAZY at MarriedIntoCrazy.com  #lovebeyondwalls #overcomingadversity #relationshipresilience #personalgrowth #lovestrategies  CHAPTERS: 00:00 - Intro 00:54 - How Carrie and Lando Met 06:36 - Carrie and Lando's First Date 10:25 - Lando's Surprise: Carrie's Jail Visit 14:07 - Tipping Point in Relationships 18:55 - Building with Precision, Delivering with Pride 22:40 - Pillars of a Strong Marriage 26:30 - Importance of Friendship in Marriage 30:10 - Importance of Adversity in Relationships 32:40 - Turning Point in Their Relationship 34:24 - Overcoming Adversity Together 38:30 - The Power of Surrender 42:27 - Strategies for Overcoming Adversity 44:53 - How to Reach the Ministry 46:10 - The Need for Marriage Ministry 48:00 - Upcoming Ministry Plans and Initiatives 49:20 - Resources for the Formerly Incarcerated 50:03 - Future Plans for Prison and Jail Ministry

What does it take to drop world-class riders like Van der Poel, Simmons, and Yates on a Tour de France mountain stage? For Ben Healy, it wasn't just power or tactics — it was fueling. Healy consumed nearly 140g of carbohydrates per hour on his way to a dominant solo win on Stage 6, and today we're breaking down exactly how he did it. With insights from WorldTour nutritionist Dr. Sam Impey, this video explores why fueling has become the new performance frontier — and what amateur cyclists can learn from it. We cover gut training, carb strategies, and why most cyclists are under-fueled, not under-trained. Surfshark - Online security starts with a VPN and I trust Surfshark. Go to⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://surfshark.com/roadman⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ and use code roadman at checkout to get 4 extra months of Surfshark VPN.NOMIO is clinically proven to:Lower lactate levels, Reduce oxidative stress, Improve training adaptations And deliver a noticeable boost from the very first dose. Go to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.drinknomio.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ and check out this game changing supplement. 4iiiiReady to elevate your cycling game? Trust the 4iiii PRECISION 3+ Powermeter—precision, performance, and peace of mind, all in one.Learn more by visiting http://www.4iiii.comBIKMO Whether it's theft, damage, crashes, racing or travel, Bikmo's got your back. Their in-house claims team makes the process fast and painless, and here's the kicker — with 50% off multi-bike cover, you can protect all your bikes, and even your family's or mates' bikes, under one simple policy.Make sure you're covered - check the details in your policy docs. T&Cs apply.Head over to https://bikmo.com/uk/ and use the code ROADMAN to get covered & save money.REAPCustom Carbon Composition Bikes made in the UK. REAP's gravel bike is set to redefine gravel riding with 50mm+ tyre clearance https://reapbikes.com/

In this episode of the HealthSpan Podcast, Dr. Robert Todd Hurst, MD, FACC, FASE sits down with Dr. Dr. Hamed Abbaszadegan, MD, MBA, FACP, FAMIA,to explore how artificial intelligence is reshaping the future of healthcare. They discuss everything from AI-powered clinical decision-making and ambient medical notetaking to the promise (and pitfalls) of predictive health modeling and personalized care.  Dr. Hamed Abbaszadegan is a double board-certified internist and clinical informaticist. He currently serves as a physician executive at Stanson Health and is a recognized leader in clinical informatics. Formerly the director of the Clinical Informatics Fellowship at the University of Arizona College of Medicine – Phoenix, he combines real-world hospital experience with cutting-edge technology insight.   Key Time Stamps:  00:40 – Introduction to Dr. Hamed  01:45 - AI's role in healthcare  05:00 – The evolution from paper charts to electronic records and AI support  07:05 – Ambient tech and how it eases physician burden  08:30 – AI-generated patient summaries and real-world applications   10:00 – Potential future of AI support in clinical evaluation   13:10 – Dr. Hamed's vision of healthcare: Predictive modeling   16:20 – Communicating risk: How AI may help patients make better decisions   20:18 – Precision medicine and interoperability challenges  22:15 – Natural language processing   24:35 – AI, the future of medical assistants   26:50 – Standards in healthcare AI and the USB-C analogy  29:20 – Can healthcare get to AI more efficiently than previous technologies  31:00 – AI's hidden presence in modern imaging and clinical tools  33:25 – Reviving the doctor-patient relationship through technology  35:35 – What is clinical informatics and how Dr. Hamed found his path to it  39:25 – A peek into his side project: The Secret Job Society podcast  This information is for educational purposes only and is not medical advice. Don't make any decisions about your medical treatment without first talking to your doctor.    Connect with Dr. Hamed here:   https://www.linkedin.com/in/hamedabbaszadegan/   abbaszadeganmdmba@gmail.com  Connect with HealthspanMD:  https://www.linkedin.com/company/healthspanmd/   https://www.facebook.com/healthspanmd   https://www.instagram.com/healthspanmd/  https://quiz.healthspanmd.com/    

Precision medicine has long guided cancer treatment by matching therapies to tumor mutations, but the emerging field of predictive genomics aims to take this further by factoring in a patient's genetics, health history, and environment to better predict drug response. Ask ChatGPT

Chad from Night Force Precision Optics visited "On The Range Podcast" hosted by Rick Hogg and Mark Kelley.  Find Nightforce Optics here : https://www.nightforceoptics.com/  Visit the SHOW at: https://ontherangepodcast.com Mark Kelley: https://kelleydefense.com  Rick Hogg: https://warhogg.com  Don't miss out on exclusive bonus content for "CREW" members after the show, and make sure to visit ONTHERANGEPODCAST.COM  to sign up and more information on upcoming events. Become 1% Better Everyday!!  JOIN Order Your Copy of “The Firearms Training Notebook”: https://amzn.to/3DfIOkz Listen to On The Range Podcast at - Apple - https://podcasts.apple.com/us/podcast... Spotify - https://open.spotify.com/show/0GBzNxH... Please subscribe to the show on the podcast platform you listen to, and leave us a rating and review to help increase our reach. Thank you! Artist: TrackTribe “Riffs For Days” https://www.youtube.com/watch?v=SBw0kBJlaVU Artist: Jimena Contreras “Alpha Mission” https://www.youtube.com/watch?v=RWi3CangMgQ&list=PL-0N3ETTFkNvksN9dMRY7utkQB0y6bEP-  For full episodes visit: www.ontherangepodcast.com ! Hosted by Mark Kelley and Rick Hogg.

Are you ready to make more confident bull-buying decisions that truly move your ranch forward? In this episode, Shaye Wanner visits with Marty Ropp of Allied Genetic Resources to discuss how commercial cow-calf producers can leverage genomics through the Right Bull program to select bulls that align with their goals and cows. Marty shares how precision mating, large-effect genes, and genomic compatibility are revolutionizing herd improvement—saving time, reducing risk, and increasing uniformity and profitability. Whether you're buying one bull or managing hundreds, this episode will help you understand how to turn genetics into ROI. What You'll Learn: The biggest risks and missed opportunities in bull selection How the Right Bull program matches bulls to your cow herd What “large-effect genes” are and why they matter How both small and large producers can benefit What it costs to get started—and why it pays off Timestamps: 00:00 – Intro & Marty Ropp's background 01:45 – Why Marty bet on the beef industry 03:50 – Top risks in bull selection 05:30 – Defining goals for genetic selection 06:40 – How the Right Bull program works 11:20 – What large-effect genes mean for your herd 13:30 – Example of bull ranking and results 17:35 – How Right Bull is different from other programs 19:30 – Costs and return on investment 23:30 – Seedstock provider involvement and response 26:30 – Who this program is best suited for 28:15 – Breed flexibility & customization 31:45 – Marty's reflections on his early career 33:10 – Final thoughts & how to connect

Have you ever wondered how to transform from being nice to truly being noticed? Monica Rivera, a personal branding and communication strategist, joins Dr. mOe Anderson to share her journey from the Bronx to the spotlight, offering invaluable insights on personal branding and resilience. Discover how to harness your unique voice and redefine perceptions in the workplace.Memorable Quotes from Monica Rivera:"To be noticed, you must ring your own bell—waiting for recognition can keep you invisible.""Capturing attention doesn't require loudness; it requires being compelling and interesting."Key Points:Personal Branding with PEP: Monica introduces her PEP framework—Posture, Energy, and Precision—to elevate your personal brand and ensure your contributions are recognized.Breaking Stereotypes: Learn strategies for challenging workplace stereotypes and claiming your space at the table without altering your natural personality.Public Speaking Tips: Monica discusses how quieter individuals can excel in public speaking by embracing storytelling and compelling delivery, rather than volume.Thought Leadership and Storytelling: Emphasize the importance of expressing personal opinions and sharing personal stories to stand out in a crowded market.Chapter Breakdown:(0:00:01) Empowering Personal Branding for Success(0:08:47) Breaking Gender Stereotypes in Leadership(0:14:38) Elevating Public Speaking Impact Through Authenticity(0:22:46) Crafting Thought Leadership and Personal Presence(0:29:04) Mastering Body Language, Energy, Precision(0:37:45) Elevate Your Personal Branding and PitchingResources Mentioned:Monica Rivera's website for personal branding resources and the Authority Accelerator https://www.youwannadowhat.com/"Hispanic Rising Voices" co-authored by Monica RiveraSubscribe now and let's ignite your personal growth journey together, one empowering conversation at a time!Learn more about Dr. mOe's services and books on her website at www.drmOeAnderson.com. Follow on social media!  @drmOeandersonElevate your public speaking skills with 1x1 or online Public Speaking Coaching.Want to feature your business on this podcast or book Dr. mOe for a speaking engagement? Contact her today! info@drmoeanderson.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/perpetual-moetion-with-dr-moe-anderson--5831364/support.

Lead Head Brigade, get ready! Talking Lead hits the Leadquarters with a sharp focus on long-range shooting. Join experts Charlie Melton (ex-Navy SEAL, CharlieMikePrecision), Jim Gilliland (record-setting sniper, 1,367-yard shot), and Brad Stair (master gunsmith, Performance Guns) for insights on precision skills, top-tier gear, and stories like the 5,000-yard .408 Tejas shot. From techniques to myth-busting, we equip shooters, hunters, and competitors with pro tips for mastering distance. Visit Jim @long_gunner, Charlie @charliemelton13 and Brad @tejas_rifles on Instagram. Email questions to talkinglead@gmail.com. Subscribe on Apple, Spotify, or RUMBLE (for video) for more! Stay focused and keep Leaducating The Unleaducated!